Cantel Medical (CMD) Given Media Impact Score of 0.27

Headlines about Cantel Medical (NYSE:CMD) have been trending positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Cantel Medical earned a daily sentiment score of 0.27 on Accern’s scale. Accern also gave news headlines about the company an impact score of 47.1625794890703 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Cantel Medical (NYSE:CMD) traded up $0.45 on Wednesday, reaching $102.55. The company had a trading volume of 99,231 shares, compared to its average volume of 147,518. Cantel Medical has a 1 year low of $69.21 and a 1 year high of $108.00. The firm has a market cap of $4,250.00, a PE ratio of 56.66 and a beta of 1.24. The company has a debt-to-equity ratio of 0.31, a current ratio of 2.44 and a quick ratio of 1.48.

Cantel Medical (NYSE:CMD) last released its earnings results on Thursday, September 28th. The company reported $0.54 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.52 by $0.02. Cantel Medical had a return on equity of 17.42% and a net margin of 9.50%. The firm had revenue of $205.50 million during the quarter, compared to analysts’ expectations of $200.32 million. Cantel Medical’s revenue was up 14.8% compared to the same quarter last year. equities research analysts anticipate that Cantel Medical will post 2.35 EPS for the current year.

The business also recently announced a Semi-Annual dividend, which will be paid on Wednesday, January 31st. Investors of record on Wednesday, January 17th will be paid a dividend of $0.085 per share. This represents a yield of 0.17%. This is a boost from Cantel Medical’s previous Semi-Annual dividend of $0.07. The ex-dividend date of this dividend is Tuesday, January 16th. Cantel Medical’s payout ratio is presently 7.73%.

Separately, Needham & Company LLC reissued a “hold” rating on shares of Cantel Medical in a research note on Friday, September 1st. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $87.50.

In other news, Director George L. Fotiades sold 6,000 shares of the company’s stock in a transaction dated Friday, October 13th. The stock was sold at an average price of $95.23, for a total transaction of $571,380.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Chairman Charles M. Diker sold 20,500 shares of the company’s stock in a transaction dated Wednesday, October 4th. The stock was sold at an average price of $99.15, for a total value of $2,032,575.00. The disclosure for this sale can be found here. Insiders have sold a total of 36,368 shares of company stock valued at $3,576,028 over the last three months. 12.30% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another site, it was stolen and republished in violation of United States & international copyright & trademark law. The original version of this report can be viewed at

Cantel Medical Company Profile

Cantel Medical Corp. is a provider of infection prevention products and services in the healthcare market. The Company’s operating segments include Endoscopy; Water Purification and Filtration; Healthcare Disposables, and Dialysis. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies.

Insider Buying and Selling by Quarter for Cantel Medical (NYSE:CMD)

Receive News & Ratings for Cantel Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical and related companies with's FREE daily email newsletter.

Leave a Reply